PD
CPRX

Point72 (DIFC)’s Catalyst Pharmaceutical CPRX Stock Holding History

Point72 (DIFC)’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-6,636
Closed -$106K – 1535
2024
Q1 		$106K Buy
+6,636
New +$100K ﹤0.01% 1086

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Point72 (DIFC)'s CPRX Position: Q2 2024 in Review

Point72 (DIFC) sold out of Catalyst Pharmaceutical (CPRX) in Q2 2024, closing a stake of 6,636 shares — an estimated $106K sold.

Point72 (DIFC) first reported a position in CPRX in Q1 2024 and held it in 1 quarter. The position peaked at $106K in Q1 2024. 271 funds tracked by Wall St. Rank hold CPRX as of Q2 2024.

  • Point72 (DIFC) reported no remaining Catalyst Pharmaceutical position as of Q2 2024 after selling out during the quarter.
  • Point72 (DIFC) sold 6,636 Catalyst Pharmaceutical shares in Q2 2024, an estimated $106K.
  • Point72 (DIFC) first reported a position in Catalyst Pharmaceutical in Q1 2024 and held it in 1 quarter.
  • Point72 (DIFC)'s Catalyst Pharmaceutical position peaked at $106K in Q1 2024.
  • 271 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2024.

Based on Point72 (DIFC)'s 13F filing for Q2 2024, filed 14 Aug 2024.